| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 795.9% | Noble Capital Markets | → $5.25 | Initiates Coverage On | → Outperform |
What is the target price for YS Biopharma Co (YS)?
The latest price target for YS Biopharma Co (NASDAQ: YS) was reported by Noble Capital Markets on November 13, 2023. The analyst firm set a price target for $5.25 expecting YS to rise to within 12 months (a possible 795.90% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for YS Biopharma Co (YS)?
The latest analyst rating for YS Biopharma Co (NASDAQ: YS) was provided by Noble Capital Markets, and YS Biopharma Co initiated their outperform rating.
When is the next analyst rating going to be posted or updated for YS Biopharma Co (YS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of YS Biopharma Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for YS Biopharma Co was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating YS Biopharma Co (YS) correct?
While ratings are subjective and will change, the latest YS Biopharma Co (YS) rating was a initiated with a price target of $0.00 to $5.25. The current price YS Biopharma Co (YS) is trading at is $0.59, which is within the analyst's predicted range.